Neumora Therapeutics
NMRA
88 hedge funds and large institutions have $725M invested in Neumora Therapeutics in 2024 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 9 closing their positions.
311% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 9
47% more funds holding
Funds holding: 60 → 88 (+28)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
4.52% more ownership
Funds ownership: 28.65% → 33.17% (+4.5%)
3% less capital invested
Capital invested by funds: $745M → $725M (-$19.4M)
6% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 18
83% less call options, than puts
Call options by funds: $75K | Put options by funds: $453K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$57.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.9M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$16.2M |
| 4 |
SCM
Soros Capital Management
New York
|
+$14.6M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$29M |
| 2 |
Goldman Sachs
New York
|
-$6.95M |
| 3 |
AI
Alphabet Inc
Mountain View,
California
|
-$6.9M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.08M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$2.4M |
NMRA Hedge Fund Activity: Q1 2024 in Review
88 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q1 2024, worth a combined $725M — down 2.6% from $745M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new NMRA positions and 9 closed out — a net gain of 28 holders — while 17 added to existing stakes and 18 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $57.9M. The largest seller was HHLR Advisors, exiting entirely with an estimated $29M sold.
- 88 institutional investors held Neumora Therapeutics (NMRA) as of Q1 2024, up from 60 in Q4 2023.
- Funds reported $725M of Neumora Therapeutics stock for Q1 2024, down 2.6% quarter-over-quarter.
- 37 funds opened new Neumora Therapeutics positions in Q1 2024 and 9 closed out, a net change of +28 holders.
- The largest Neumora Therapeutics buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $57.9M added.
- The largest Neumora Therapeutics seller in Q1 2024 was HHLR Advisors, an estimated $29M sold.
Based on aggregated 13F filings for Q1 2024.